United States

People: Alkermes Plc (ALKS.O)

ALKS.O on Nasdaq

26 Oct 2016
Change (% chg)

$-1.22 (-2.24%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Dixon, Wendy 

Dr. Wendy L. Dixon Ph.D. is an Independent Director of Alkermes Plc. She has served as a director of Alkermes plc since September 16, 2011. From January 2011 to September 16, 2011, Dr. Dixon served on the Alkermes, Inc. board of directors. She has extensive experience in the pharmaceutical and biotechnology industries, combining a technical background with experience in drug development, regulatory affairs and marketing. She directed the launches and growth of more than 20 pharmaceutical products. From 2001 to 2009 she was Chief Marketing Officer and President, Global Marketing for Bristol-Myers Squibb where she served on the Executive Committee. From 1996 to 2001 she was Senior Vice President, Marketing at Merck, and prior to that, she held executive management positions at West Pharmaceuticals, Osteotech and Centocor and various positions at SmithKline and French (now GlaxoSmithKline) in marketing, regulatory affairs, project management and as a biochemist. Dr. Dixon is on the board of directors of Orexigen Therapeutics, Incyte Corporation, bluebird bio and Eleven Biotherapeutics, all publicly traded biotechnology or pharmaceutical companies, and was formerly on the board of Ardea Biosciences, Dentsply International and Furiex Pharmaceuticals. In addition, she is on the board of directors of Edimer Pharmaceuticals, a privately held pharmaceutical company. She is an advisor to the Mellon Group and the Longitude Capital Industry Advisory Board. She was a Senior Advisor to The Monitor Group, now Deloitte, through 2012. Dr. Dixon brings a depth of experience in the marketing of pharmaceutical products across a broad variety of disease states and on a global basis to our Board. Dr. Dixon has a strong technical background and direct experience in product development and regulatory affairs, and has successfully built and grown commercial organizations in the United States and Europe, each of which provide valuable insight to our Board regarding the development and commercialization of pharmaceutical products.

Basic Compensation

Total Annual Compensation, USD 89,000
Restricted Stock Awards, USD --
Long-Term Incentive Plans, USD --
All Other, USD 469,393
Fiscal Year Total, USD 558,393

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Richard Pops


Shane Cooke


James Frates


Gordon Pugh


Kathryn Biberstein


Elliot Ehrich

As Of  30 Dec 2014